• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

    1.610 UNCHANGED
    Delayed Quote Updated: 3:46 PM EDT, Oct 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 7,183
    Open 1.610
    Bid (Size) 1.550 (100)
    Ask (Size) 1.620 (100)
    Prev. Close 1.610
    Today's Range 1.600 - 1.636
    52wk Range 1.370 - 28.44
    Shares Outstanding 11,523,716
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
    Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment 
    From Aptevo Therapeutics
    Via ACCESS Newswire
    News headline image
    Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
    Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human Testing Trispecifics Combine Three Complementary Cancer-Fighting Functions in... 
    From Aptevo Therapeutics
    Via ACCESS Newswire

    Performance

    52-Week Range 94.3% below 52-week high
    1.610
    1.3752W Low 28.4452W High
    1 Week 2.7% below 1-week high
    1.571W Low 1.661W High

    Aptevo Therapeutics Inc. - Common Stock (APVO) traded between $1.37 and $28.44 over the past 52 weeks and last traded at $1.61, 94.3% below its 52-week high. Over the past week it ranged between $1.57 and $1.66.

    Past 12 Months
    +0.6%
    -14.8%
    -63.3%
    -66.9%
    -82.9%
    -94.2%
    1W +$0.01
    1M -$0.28
    3M -$2.78
    6M -$3.26
    YTD -$7.78
    1Y -$25.93

    APVO was -94.2% over the past year, -66.9% over six months, -82.9% year to date, +0.6% in the last week.

    12 Months vs Market
    APVO
    -94.2%
    DIA
    +11.6%
    SPY
    +13.1%
    QQQ
    +15.4%
    IWM
    +11.9%

    Over the past 12 months APVO returned -94.2% versus DIA (Dow) +11.6%, SPY (S&P 500) +13.1%, QQQ (Nasdaq 100) +15.4% and IWM (Russell 2000) +11.9%.

    Volume & Liquidity 0.08× 3-mo avg
    Today 7,183 3-mo avg 91.4K
    1W
    8.4K
    1M
    35.9K
    3M
    91.4K
    6M
    74.2K
    YTD
    100.3K
    1Y
    94.9K

    APVO most recently traded 7,183 shares against a 3-month average daily volume of 91.4K.

    More News

    Read More
    The trading volume of these stocks is deviating from the norm in today's session. ↗
    Via Chartmill
    News headline image
    Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
    From Aptevo Therapeutics
    Via ACCESS Newswire
    News headline image
    Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
    From Aptevo Therapeutics
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
    From Aptevo Therapeutics
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
    From Aptevo Therapeutics
    Via ACCESS Newswire
    News headline image
    Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
    From Aptevo Therapeutics
    Via ACCESS Newswire
    News headline image
    Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
    From Aptevo Therapeutics
    Via ACCESS Newswire
    News headline image
    As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category
    Via NewMediaWire
    News headline image
    Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
    Via ACCESS Newswire
    News headline image
    Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
    Via ACCESS Newswire
    News headline image
    Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
    Via ACCESS Newswire
    News headline image
    Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment
    Via NewMediaWire
    News headline image
    Aptevo Provides State of the Business Report and 2025 Financial Results
    Via ACCESS Newswire
    News headline image
    Aptevo to Participate in March 2026 Conferences
    Via ACCESS Newswire
    Gapping stocks in Tuesday's session ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
    Via ACCESS Newswire
    News headline image
    Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
    Via ACCESS Newswire
    Friday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
    Via ACCESS Newswire
    News headline image
    These stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    Top movers in Friday's session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Aptevo Therapeutics Inc. - Common Stock publicly traded?
    Yes, Aptevo Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Aptevo Therapeutics Inc. - Common Stock trade on?
    Aptevo Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Aptevo Therapeutics Inc. - Common Stock?
    The ticker symbol for Aptevo Therapeutics Inc. - Common Stock is APVO on the Nasdaq Stock Market
    What is the current price of Aptevo Therapeutics Inc. - Common Stock?
    The current price of Aptevo Therapeutics Inc. - Common Stock is 1.610
    When was Aptevo Therapeutics Inc. - Common Stock last traded?
    The last trade of Aptevo Therapeutics Inc. - Common Stock was at 10/23/26 03:46 PM ET
    What is the market capitalization of Aptevo Therapeutics Inc. - Common Stock?
    The market capitalization of Aptevo Therapeutics Inc. - Common Stock is 18.55M
    How many shares of Aptevo Therapeutics Inc. - Common Stock are outstanding?
    Aptevo Therapeutics Inc. - Common Stock has 19M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.